Levetiracetam Solution
Product Images NDC 0904-7265

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0904-7265). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of levetiracetam, showing a pyrrolidone ring attached to an ethyl group, a hydrogen atom, and a carboxamide group as the key functional groups.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A bar graph depicting the percentage of patients by treatment group, comparing Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, and the x-axis lists the treatment groups including sample sizes. Bars for Levetiracetam groups are higher than Placebo, showing increased percentages.*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar chart showing the percentage of patients achieving a specific outcome in three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, ranging from 0% to about 45%. Levetiracetam 2000 mg/day shows the highest percentage at 35.2%, followed by Levetiracetam 1000 mg/day at 20.8%, and the placebo group with 6.3%. Each bar includes the sample size and an asterisk marking statistical significance.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar chart comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The Y-axis shows the percentage of patients, with placebo at 14.4% and Levetiracetam at 39.4%, indicating a higher response rate for Levetiracetam in this sample.*

FDA Label Image

Figure 4 (Levetiracetam 05)

A bar graph comparing the percentage of patients between a placebo group and a levetiracetam group. The placebo group (N=97) shows 19.6% of patients, while the levetiracetam group (N=101) shows 44.6%. The vertical axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 5 (Levetiracetam 06)

A bar chart comparing the percentage of patients in two groups: Placebo (approximately 19.6%) and Levetiracetam (approximately 43.1%). The Levetiracetam group shows a statistically significant difference compared to placebo, as indicated by an asterisk. The chart includes sample sizes: 51 patients for placebo and 58 for Levetiracetam.*

FDA Label Image

Figure 6 (Levetiracetam 07)

Bar chart comparing the percentage of patients responding to Placebo and Levetiracetam in two groups: Placebo with 84 patients and Levetiracetam with 79 patients. The Levetiracetam group shows a higher response rate at 72.2% compared to 45.2% for Placebo.*

FDA Label Image

Principal Display Panel (5 mL Cup Label)

Label for Levetiracetam Oral Solution, USP 500 mg per 5 mL by Major Pharmaceuticals. The label includes dosage form as an oral solution, indicates institutional use only, and states the package is not child-resistant. The label displays the NDC 0904-7265-41 and the manufacturer located in Indianapolis, IN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.